Skip to main content

Incremental associations of pharmacological components in heart failure with mildly reduced or preserved ejection fraction: a systematic review and component network meta-analysis

In brief

SGLT2 inhibitors were associated with 20% fewer heart failure events

In a component analysis of randomized trials in heart failure with mildly reduced or preserved ejection fraction, SGLT2 inhibitors were associated with a 20% lower risk of cardiovascular death or first heart failure hospitalization, driven mainly by fewer hospitalizations. Mineralocorticoid receptor antagonists also showed benefit, but the sparse evidence limits confidence in some class estimates and does not establish which combinations work best.

Journal
Expert review of clinical pharmacology (Q1)
Published
20 November 2026
Study design
Systematic review / meta-analysis of RCTs
Evidence level
Level 1, High (CEBM 1a)
Authors
Mohammad Ali Omrani, Bala Swetha Baskaran, Atefeh Jafari, Lujain Ez Eddin, Fatemeh Ahmadi, Manik Chhabra, et al.
PMID
43065287
DOI
10.1080/17512433.2026.2768391

Why clinicians should know about it

Abstract

INTRODUCTION: We conducted a component network meta-analysis (CNMA) of phase 3/4 randomized trials to evaluate incremental effects of pharmacological therapies in heart failure with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF; LVEF > 40%). METHODS: MEDLINE, Embase, and Cochrane were searched through 1 August 2025 (updated 30 March 2026). We performed an additive CNMA evaluating cardiovascular death or first heart failure hospitalization (HFH) and assessed certainty of evidence. RESULTS: Twenty-four trials and five secondary reports were included. The primary network was sparse (10 trials, 12 regimens), constraining interaction detection and component stability. Incretin-based interventions (pooling semaglutide and tirzepatide, iHR 0.69, 95% CI 0.53-0.91), SGLT-2 inhibitors (0.80, 0.74-0.88), ARNis (0.82, 0.68-0.99), and MRAs (0.89, 0.81-0.98) showed significant component associations, driven principally by fewer HFHs. No drug class significantly reduced mortality. SGLT-2 inhibitors and MRAs remained significant across sensitivity analyses except LVEF ≥ 50%, with SGLT-2 inhibitors most precise. ARNi benefits lost significance under stricter background therapy thresholds (>60%) and contemporary trial restrictions. Evidence for incretins was low-certainty and sensitive to trial selection. CONCLUSIONS: SGLT-2 inhibitors and MRAs provide the most robust incremental benefit, while evidence for other drug classes remains context-dependent. These findings should guide research priorities rather than define combination regimens. PROTOCOL REGISTRATION: http://www.crd.york.ac.uk PROSPEROidentifier is CRD420251107058.

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.